ASCO GU 2026

Encouraging new data in Prostate cancer

Combination is the way to go - but how to select?

Precision medicine for prostate cancer

PSA-dynamics in TALAPRO-2

Actinium radioligand therapy

Benefit of PARPi + ABI combination

EZH2 oral molecule to enhance ARPI

New Mode of Action in mCRPC

Patient Preferences for ARPI vs ADT in nmHSPC: A Global…

Prolonged PSA declines with normalization of…

Radium-223 + Enzalutamid

T-cell engager - first in human

T-Cell-Engager

Adjuvant therapy for RCC: Progress made, key questions…

Post-IO in RCC: Promising Efficacy, Evolving Survival…

New second-line option in mRCC

Combination therapy in adjuvant RCC

Belzutifan + Lenvatinib: A New Second-Line Approach in…

Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab

HIF based combination are here to stay

New follow-up therapy with lenvatinib + belzutifan

Real World Data - RCC

Balancing efficacy and toxicity: the challenge in high…

Advances in the Adjuvant Treatment of RCC

Treatment after immunotherapy in aRCC: always a complex…

Upcoming new standard for adjuvant RCC

Equilibrar eficacia y toxicidad: el desafío en el ccRCC…

BCG plus CPI for NMIBC - do the benefits outweigh the…

Closing the gap for platin eligibility

The future is bright, but complex

A new class of drug in luminal UC

Urinary ctDNA vs. plasma ctDNA

Perioperative EV + P - the new standard?!

Promising data - how to stratify the patients for the…

MIBC - time for a historic paradigm shift?

Perioperative EV+Pembrolizumab in MIBC

ctDNA testing: Who, how and how often?

New perioperative standard for MIBC

EV+P new SOC in MIBC

New machanism of action in pts with UC

ctDNA from plasma and urine in MIBC

ctDNA dynamics in the IMvigor011 trial

Rethinking the use of HER2neu in routine clinical…

EV + P : nouveau standard de traitement pour le TVIM

Une nouvelle classe de médicaments pour le carcinome…

Dinámica del ctDNA en el ensayo IMvigor011